1,000-Patient study to decode widespread artery disease
NCT ID NCT07151183
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will collect DNA samples and medical records from 1,000 people with panvascular disease, a condition where arteries in multiple parts of the body are narrowed or blocked. Researchers will analyze this data to better understand what causes the disease and how it progresses. The goal is to improve diagnosis and find more effective treatments for conditions like heart attack, stroke, and peripheral artery disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could lead to better ways to diagnose and treat panvascular diseases, potentially improving patient outcomes.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly test any new therapy, and results may take years to influence clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2024
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with panvascular diseases
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female aged 18 to 80 years old; 2. Diagnosed or suspected panvascular disease, defined as the presence of atherosclerotic lesions in at least two or more vascular regions, such as intracranial arteries, carotid arteries, coronary arteries, aorta, and peripheral arteries; 3. Voluntary participation in this study and provision of signed informed consent. Exclusion Criteria: 1. Severe hemodynamic instability; 2. Severe cardiac dysfunction (EF \< 30%); 3. Severe arrhythmias; 4. Severe valvular heart disease; 5. Cardiomyopathy caused by non-coronary artery diseases; 6. Non-atherosclerotic coronary artery disease (e.g., coronary artery dissection, embolism, etc.); 7. Severe non-cardiovascular diseases; 8. Women who are pregnant or breastfeeding; 9. Individuals who refuse to provide signed informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Harbin Medical University
RECRUITINGHarbin, Heilongjiang, 150086, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nurse and a neighbor help tame chronic disease?
- Two eggs a day put to the test for heart health
- A soft patch that watches your heart beat in real time
- Can a Once-Daily form of tacrolimus spare liver transplant patients from side effects?
- Inhaled drug aims to ease dangerous lung blood pressure in scarred lungs
- Massive Real-World database aims to map how chronic diseases interact